Internship

Summer 2024 – Decision Intelligence Internship

Posted on 2/14/2024

Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$27 - $30/hr

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Physical presence at the BMS worksite or physical presence in the field is a necessary job function of this role, which the Company deems critical to collaboration, innovation, productivity, employee well-being and engagement, and it enhances the Company culture. Applicants can request a reasonable workplace accommodation/adjustment prior to accepting a job offer.

Category
Data & Analytics
Required Skills
Python
Data Science
R
Git
SQL
Tableau
Marketing
Data Analysis
Requirements
  • BA/BS in a quantitative area of study
  • Masters in Data science or related degree preferred
  • 2+ years of Analytical Experience
  • Superior knowledge of secondary healthcare data
  • In-depth understanding of applied analytics and advanced statistical models
  • Proficiency in R/Python, SQL, Tableau, MS Office Suite
Responsibilities
  • Research new solutions for commercial impact measurement
  • Automate data pipelines and enhance current tools
  • Develop new tools to improve the speed and quality of commercial marketing decisions
  • Develop FASST Layer for KDA data elements to enable faster data processing times
  • Compile response curves across brands by channel to develop generic response curves by channel/therapy area
  • Develop a database to guide omni-channel goal setting by compiling, spend, activity, impact and ROI metrics and linking response curves across brands/channels
  • Compile key stats for key brands in a user friendly dashboard by engaging with cross matrix partners
  • Develop a POV on adstock and ML models for running marketing mix analyses
  • Transfer KDA and test control codes on github
Desired Qualifications
  • Masters in Data science or related degree

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, providing affordable alternatives that meet the same quality and safety standards as their branded counterparts. Unlike many competitors, BMS emphasizes sustainability and corporate responsibility, aiming to positively impact patients and the healthcare system. Their goal is to improve patient outcomes by making both innovative and affordable medicines widely available.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of 2seventy bio enhances BMS's capabilities in cancer cell therapy.
  • Rising demand for biosimilars opens new revenue streams for BMS.
  • Digital health technologies improve R&D efficiency, reducing costs and time to market.

What critics are saying

  • Increased competition in oncology could impact BMS's market share.
  • Patent expirations like Revlimid may lead to revenue loss from generics.
  • FDA scrutiny on drug pricing could pressure BMS's profit margins.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

CMMB
Mar 24th, 2025
Our Values, Your Impact

In partnership with Bristol Myers Squibb, Catholic Medical Mission Board Inc. is playing a role in building the infrastructure and workforce to bring quality cancer care to rural Kenya.

PR Newswire
Mar 20th, 2025
Bristol Myers Squibb Appoints Osama Braiwish As General Manager For Saudi Arabia Gulf Countries

RIYADH, Saudi Arabia, March 20, 2025 /PRNewswire/ -- Bristol Myers Squibb, a leading global biopharmaceutical company, has recently appointed Osama Braiwish as its General Manager for Saudi Arabia and Gulf Countries, an affiliate covering Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan

Investors Hangout
Mar 20th, 2025
Bristol Myers Squibb Welcomes New Leadership in Gulf Region

Bristol Myers Squibb, a leader in the global biopharmaceutical sector, has appointed Osama Braiwish as its General Manager for the Gulf region, thereby enhancing its capacity to serve medical needs across various specialties.

Business Wire
Mar 12th, 2025
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all

Reuters
Mar 11th, 2025
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million

March 11 (Reuters) - Bristol Myers Squibb (BMY.N) will acquire 2seventy bio (TSVT.O) for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday.

INACTIVE